CJC-1295 10mg

CJC-1295 no DAC (Mod GRF 1-29) Overview

This is an interesting peptide because it came as a result of growth hormone releasing hormone analysis which showed that “only” the first 29 amino acids showed the same potential as the entire 44 amino acid structure. From this point on, researchers focused solely on these 29 amino acids, attempting to modify it in such a way to prolong its half life and effectiveness.

This led to the development of Mod (modified) GRF 1-29, also called CJC-1295. This synthetic peptide version demonstrated increased affinity towards GHRH receptors, prolonged half life, as well as some other potential benefits which we’re going to talk about below.

Diabetes and Heart Health Research

When it comes to heart health, we’ve seen some preliminary murine models research which suggest CJC-1295 no DAC positively affects overall heart rate, as well as heart’s ability to pump blood. More importantly, these animal studies showed peptide’s potential to promote cardiac tissue repair following cardiac arrest. 

Broad group of GHRH agonists also demonstrated beneficial effects in pancreatic β-cell proliferation and metabolic function improvement. Since CJC-1295 no DAC falls under this category, researchers assume it might help create a foundation for future diabetes treatment and a more effective way of managing blood glucose levels.

CJC-1295 No DAC (Mod GRF 1-29) Gastrointestinal Research

Experimental studies involving growth hormone-releasing factor (GRF) showed its potential interaction with smooth muscles of the gastrointestinal tract; more precisely, interaction between these peptides and vasoactive intestinal peptide receptors (VPAC1-R). These receptors regulate the secretion/excretion of water, salts, certain enzymes and gastric acid during digestion.

One study involving monkey test subjects clearly showed this connection when a GRF-6 application resulted in diarrheal effects. The results of the study were later corroborated in a similar study, where GRF analogues interacted with rat’s pancreatic membranes.

Growth Hormone Response Research

The relationship between hypothyroidism and impaired growth hormone release was always a common one and we’ve seen numerous studies where researchers set out to examine it in more detail. 

One such study was designed to test out this relationship and measure the GH response for GRF both before and after thyroxine (T4) replacement therapy. The study was conducted on 14 patients between 26 and 60, with thyroid gland dysfunction-caused hypothyroidism. 

The results clearly showed that, following T4 therapy, GH responsiveness to GRF significantly improved in 9 patients. Meaning, GRF still holds a lot of potential in future research, but it also shows us there are certain considerations to take into account as this therapy came with some side effects, bioavailability and dosage problems.

CJC-1295 no DAC (Mod GRF 1-29) Bioavailability and Synergistic Effect

At the beginning of the review, we noted that one of the main drawbacks of CJC-1295 is its short half life. Of course, this problem was solved with the introduction of CJC-1295 DAC - Drug Affinity Complex, responsible for prolonging this half life.

But, this short half life allows it to be combined and act well with other short acting peptides and growth hormone secretagogues. CJC-1295 no DAC is most commonly combined with:

• Ipamorelin
• Tesamorelin
• GHRP-2 and
• GHRP-6

All of which are available for purchase on our website.

References:

Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. doi: 10.1016/s0196-9781(01)00436-3. PMID: 11445245.

Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology. 1985 Jun;116(6):2643-9. doi: 10.1210/endo-116-6-2643. PMID: 2859987.

Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. doi: 10.1210/en.2019-00111. PMID: 31070727.

Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.

Clark RG, Robinson IC. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985 Mar 21-27;314(6008):281-3. doi: 10.1038/314281a0. PMID: 2858818.

Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. doi: 10.1016/s0196-9781(01)00436-3. PMID: 11445245.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.